Rapid Microbiology Testing Market Analysis and Forecast to 2031: By Product (Instrument {Automated Microbial Identification & Antimicrobial Susceptibility Testing System, Mass Spectrometers, Bioluminescence & Fluorescence-Based Detection System, PCR Syste

Rapid Microbiology Testing Market Analysis and Forecast to 2031: By Product (Instrument {Automated Microbial Identification & Antimicrobial Susceptibility Testing System, Mass Spectrometers, Bioluminescence & Fluorescence-Based Detection System, PCR Systems, Cytometers, Active Air Samplers}, Reagent & Kits {Sterility Reagents and Kits}, Consumables), By Method (Growth-Based Rapid Microbiology Testing, Cellular component-Based Rapid Microbiology Testing, Nucleic Acid-Based Rapid Microbiology Testing, Viability-Based Rapid Microbiology Testing), End-use (Clinical Disease Diagnostics, Food & Beverage testing, Pharmaceutical & Biological Drug Testing, Environmental Testing, Cosmetics and Personal Care Products Testing, Research Applications), and Region

The global rapid microbiology testing market was valued at USD 4.2 billion in 2021 and it is anticipated to grow up to USD 10.7 billion by 2031, at a CAGR of 9.8% during the forecast period.


Rapid microbiology testing has high sensitivity and less turnover time compared to traditional methods and is used to diagnose infectious diseases or target products by examining pathogens within a short period.

Global Rapid Microbiology Testing Market Scope and Report Structure

Market Trends and Drivers

Increasing incidence of infectious disease and cancer will drive the industry growth. The incidence of various infectious diseases such as HIV, tuberculosis, malaria, and pneumonia has increased. With a rise in the global burden of these diseases, the demand for rapid microbiology techniques for faster and accurate microbial screening, identification, and susceptibility testing against pathogens is expected to witness significant growth during the forecast period

Market Restraints and Challenges

High capital investments and low cost-benefit ratio may restraint the market growth. Significant capital investments are required for the discovery, development, and validation of efficient rapid tests. Additionally, due to the high drug attrition in clinical trials (with almost 30% of drugs failing in Phase III), diagnostic manufacturers are exposed to significant financial challenges. To gain approval for in vitro diagnostics (IVD) from regulators, manufacturers need successful Phase III clinical trials. Huge investments are required to run clinical trials and address stringent regulatory requirements, which not only affects the ability of small companies to develop tests but also severely affects innovation. Hence, along with the high amount of capital investments, the low cost-benefit ratio is hindering the growth of the rapid microbiology testing market.

Global Rapid Microbiology Testing Market Segmental Overview

The report analyses the global rapid microbiology testing market based on product, application, method, and region.

Global Rapid Microbiology Testing Market by Product

Based on product, it is segmented into instrument, reagent and kits, and consumables. Among these, the instruments segment is expected to witness significant CAGR through 2031. This is attributed to the adoption of new instruments with advanced technology. For instance, in August 2018, Illumina received approval from the China National Drug Administration for the launch of MiSeq Dx Sequencing System in China. The clinical laboratories can develop and perform next generation sequencing (NGS) tests for gene testing to determine the order of nucleotides in entire genome or targeted regions of DNA or RNA. Thus, patients and various medical institutions have increased access to next generation sequencing technology. Hence, with advanced technologies the demand of new instruments surges, thereby propelling the overall market expansion.

Global Rapid Microbiology Testing Market by Method

Based on method, it is segmented into growth-based rapid microbiology testing, cellular component-based rapid microbiology testing, nucleic acid-based rapid microbiology testing and viability-based rapid microbiology testing. Among them, the growth-based rapid microbiology testing segment accounted for USD 12.6 billion in 2021 as it offer a greater sensitivity. Factors such as increased focus on the early detection of infectious disease increased funding for R&D and increased incidence of infectious disease and cancer. Moreover, growth-based RMMs provide either a quantitative cell count, estimation of viable cell concentration, information regarding the presence of a specific microorganism, or a microbial identification. However, the ability of these RMM systems are limited in scope in that they cannot be used to perform multiple assays using a single technology platform.

Global Rapid Microbiology Testing Market by Application

Based on application, it is segmented into clinical disease diagnostics, food & beverage testing, pharmaceutical & biological drug testing, environmental testing, cosmetics and personal care products testing, research applications and others. In 2021, the clinical disease diagnostics segment accounted for the largest share of the rapid microbiology testing market. The increasing incidence of infectious disease and cancer is driving the growth of this segment. Clinical diagnosis made on the basis of medical signs and reported symptoms, rather than diagnostic tests. Moreover, the main clinical manifestations of COVID-19 include fever, cough, fatigue, headache, myalgia among other less frequent symptoms. However, the presentation of symptoms varies among children, young adult and the elderly.

Geographical Analysis of Global Rapid Microbiology Testing Market

Region-wise, it is studied across North America, Europe, Asia Pacific, and the Rest of the World. North America therapeutic respiratory devices market captured significant market share in 2021 and is expected to grow significantly during the forecast years owing to the presence of sophisticated healthcare facilities in the U.S. and Canada. Also, the increasing healthcare expenditure due to rising awareness will augment the market share. Moreover, the increasing prevalence of COVID-19 infections along with rising healthcare spending is expected to boost the market outlook in the forthcoming years. For instance, according to the data published by USA Facts, there were 67,008 confirmed cases of COVID-19 infection on February 25, 2022. This number is increasing every day, thus increasing the demand for COVID-19 detection kits. All these factors along with the technological advancements in virus detection technologies increase the demand for COVID-19 detection kits, thereby propelling the regional market statistics.

Major Players in the Global Rapid Microbiology Testing Market COVID-19 Impact

The emergence of the COVID-19 pandemic has changed the delivery of medical care across the world. The COVID-19 pandemic has significantly affected the rapid microbiology testing market. The market has faced challenges in the manufacturing and supply chain, such as delivering products to end users in a timely manner as well as attending to an uneven demand for the products and services in the sector. In addition, a dearth of skilled laboratory professionals to conduct/study diagnostic tests, limited operations in most of the industries, inadequate funding for research and academic institutes, and challenges in providing essential/post-sales services due to lockdowns have led to the reduced supply of rapid microbiology testing products to end users. Research institutes are one of the major end users of rapid microbiology testing products.


As the pandemic resulted in the temporary closure of several institutes across the globe, this end-user segment has been affected drastically in the last few months. Despite the challenging situation, industries are gradually recovering from the impact, and supply and distribution channels have also resumed. Also, significant research activities on SARS-CoV-2-related vaccines, diagnostic test kits, and drugs by major countries (such as the US, Russia, China, and India) have increased the demand for rapid microbiology testing.

Recent Developments

• In March 2022, Biofire launched the BIOFIRE® FILMARRAY® 2.0 instrument and the single-use "molecular lab in a pouch" disposable for fast, accurate mycoplasma testing.
• In August 2021, Agilent Technologies Inc. revealed that its PD-L1 IHC 22C3 pharmDx assay gained CE-IVD marking for use in the treatment of esophageal cancer with KEYTRUDA immunotherapy in Europe.
• In April 2021, Roche launched its Elecsys Anti-p53 immunoassay to boost in vitro quantitative determination of anti-p53 antibodies to help diagnose throat, bowel, and breast cancer.
• In October 2020, Merck KGAA collaborated with Mammoth Biosciences for the development, scale up and commercial production of CRISPR- based SARS-COV-2 diagnostic test.
• In September 2020, Bruker Corporation has an acquisition with Canopy Bioscience LLC which enhanced bruker’s offerings in targeted multi-omics and fluorescence-based imaging technique.

Frequently Asked Questions

Q1. How big is the rapid microbiology testing market market?Ans. The global rapid microbiology testing market size was USD 4.2 billion in 2021 and is anticipated to reach USD 10.7 billion in 2031, growing at a rate of 9.8% from 2022 to 2031.
Q2. What is the rapid microbiology testing market growth rate?Ans. The growth rate of the rapid microbiology testing market is 9.8%.
Q3. Which region holds a major market share for the sepsis diagnostics market?Ans. North America holds a major market share of the rapid microbiology testing market in 2021.
Q4. Which segment accounted for the largest rapid microbiology testing market share?Ans. By end user, the healthcare segment accounted for the largest rapid microbiology testing market share.
Q5. Who are the key players in the sepsis diagnostics market?Ans. The global rapid microbiology testing market report includes players such as
Q6. What are the factors driving the rapid microbiology testing market growth?Ans. The major factors driving the growth of the market are the rising incidence of HAI’s across the globe.
Q7. What are the key growth strategies of rapid microbiology testing market players?Ans. The key growth strategies of rapid microbiology testing market players are product launch and product approval.
Q8. Which region will provide more business opportunities for the rapid microbiology testing market during the forecast period?Ans. The Asia-Pacific region will provide more business opportunities for the rapid microbiology testing market during the forecast period.

Please Note: This report will be delivered by publisher within 3-4 business days of order confirmation.